PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Breast
HCI-001
Model Details
Patient
PDX Model
Drug Studies
Histology
Metastasis
Patient Treatment
Patient Information for Model: HCI-001
Contact Model Developer
Model Contact
Model: HCI-001
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email:
Alana.Welm@hci.utah.edu
Patient Information
Clinical Timeline
Color Keys:
Positive
Negative
N/A
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: HCI-001
Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Drug Studies for Model: HCI-001
Treatment Response Across All Studies
CR <=-95% to -100%
PR <-30% to >-95%
SD >=-30% to +20%
PD >=+20%
NA
Drug Study: T123-T130
Study Metadata
Study ID:
T123-T130
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
2
Mouse Strain:
PI:
Alana Welm
Study Title:
Tolinapant Efficacy Study
Treatments:
Tolinapant
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Control
Vehicle
Treatment
Tolinapant
20
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Vehicle
21
943
PD
Tolinapant
21
748
PD
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Drug Study: Legacy2013
Study Metadata
Study ID:
Legacy2013
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
4
Mouse Strain:
PI:
Alana Welm
Study Title:
Legacy 2013 - PDX Efficacy Study
Treatments:
Paclitaxel, Doxorubicin, Doxorubicin+Cyclophosphamide
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Control
Vehicle
6
Treatment
Paclitaxel
11
10
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Vehicle
57
657
PD
Paclitaxel
57
158
PD
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Drug Study: Legacy2017
Study Metadata
Study ID:
Legacy2017
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
16
Mouse Strain:
PI:
Alana Welm
Study Title:
Legacy 2017 - PDX Efficacy Study
Treatments:
5-Fluorouracil, MK-1775, Olaparib, Ponatinib, Doxorubicin, AZD8186, Palbociclib, TAK228, Palbociclib+AZD8186, Palbociclib+TAK228, Apitilosib, Everolimus, Gemcitabine, Paclitaxel, Lapatinib
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 11
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Treatment
Ponatinib
4
30
Treatment
Paclitaxel
3
20
Treatment
Olaparib
4
50
Treatment
TAK228
4
Treatment
5-Fluorouracil
5
1
Control
Vehicle
4
Treatment
Palbociclib
6
Treatment
AZD8186
5
Treatment
MK-1775
3
30
Treatment
Palbociclib+AZD8186
7
Treatment
Palbociclib+TAK228
5
Total arms showing: 11
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 11
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Ponatinib
28
537
PD
Paclitaxel
42
78
PD
Olaparib
28
304
PD
TAK228
22
94
PD
5-Fluorouracil
28
726
PD
Vehicle
28
1442
PD
Palbociclib
22
292
PD
AZD8186
22
153
PD
MK-1775
28
546
PD
Palbociclib+AZD8186
22
145
PD
Palbociclib+TAK228
22
106
PD
Total treatment results showing: 11
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Histology Information for Model: HCI-001
There are no histology images for this model.
Metastasis Information for Model: HCI-001
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar
Patient Treatment Information for Model: HCI-001
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
Pathologic Response
Reason Stopped
10
Paclitaxel
Neoadjuvant
39.67
39.91
88 days
Progressive disease
No Response
20
Radiation Therapy
Adjuvant
40.08
40.16
29 days
Progressive disease
No Response
25
Doxorubicin Liposomal
Adjuvant
40.16
40.25
33 days
Stable Disease
Complete Response
Patient Responded
30
Adriamycin
Adjuvant
40.33
40.41
29 days
Progressive disease
No Response
Patient Died
Please wait...
